Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:162676rdf:typepubmed:Citationlld:pubmed
pubmed-article:162676lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:162676lifeskim:mentionsumls-concept:C0012201lld:lifeskim
pubmed-article:162676lifeskim:mentionsumls-concept:C0024977lld:lifeskim
pubmed-article:162676lifeskim:mentionsumls-concept:C1281429lld:lifeskim
pubmed-article:162676lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:162676lifeskim:mentionsumls-concept:C0733636lld:lifeskim
pubmed-article:162676pubmed:issue3lld:pubmed
pubmed-article:162676pubmed:dateCreated1992-6-12lld:pubmed
pubmed-article:162676pubmed:abstractTextFifty obese patients were entered into a 12-week parallel group study of mazindol with diethylpropion in a general practice group. Both drugs produced weight loss, but patients on mazindol lost 19.9 lbs in 12 weeks, while those on diethylpropion lost 11.6 lbs, a statistically significant difference (p less than 0.01). At each visit during the trial, patients had lost more weight with mazindol, but this was only significant statistically in the period 8-12 weeks (p less than 0.01). Patients developed tolerance to the effect of diethylpropion in the last period (8-12 weeks) but this was not evident in those patients taking mazindol. The number of side-effects was less in the mazindol group and mainly of an adrenergic, peripheral type, while those in the diethylpropion group are mainly of the central stimulant type.lld:pubmed
pubmed-article:162676pubmed:languageenglld:pubmed
pubmed-article:162676pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:162676pubmed:citationSubsetIMlld:pubmed
pubmed-article:162676pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:162676pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:162676pubmed:statusMEDLINElld:pubmed
pubmed-article:162676pubmed:issn0300-0605lld:pubmed
pubmed-article:162676pubmed:authorpubmed-author:MurphyJ EJElld:pubmed
pubmed-article:162676pubmed:authorpubmed-author:DonaldJ FJFlld:pubmed
pubmed-article:162676pubmed:authorpubmed-author:CrowderDDlld:pubmed
pubmed-article:162676pubmed:authorpubmed-author:MollaA LALlld:pubmed
pubmed-article:162676pubmed:issnTypePrintlld:pubmed
pubmed-article:162676pubmed:volume3lld:pubmed
pubmed-article:162676pubmed:ownerNLMlld:pubmed
pubmed-article:162676pubmed:authorsCompleteYlld:pubmed
pubmed-article:162676pubmed:pagination202-6lld:pubmed
pubmed-article:162676pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:162676pubmed:meshHeadingpubmed-meshheading:162676-H...lld:pubmed
pubmed-article:162676pubmed:meshHeadingpubmed-meshheading:162676-O...lld:pubmed
pubmed-article:162676pubmed:meshHeadingpubmed-meshheading:162676-F...lld:pubmed
pubmed-article:162676pubmed:meshHeadingpubmed-meshheading:162676-M...lld:pubmed
pubmed-article:162676pubmed:meshHeadingpubmed-meshheading:162676-A...lld:pubmed
pubmed-article:162676pubmed:meshHeadingpubmed-meshheading:162676-M...lld:pubmed
pubmed-article:162676pubmed:meshHeadingpubmed-meshheading:162676-W...lld:pubmed
pubmed-article:162676pubmed:meshHeadingpubmed-meshheading:162676-D...lld:pubmed
pubmed-article:162676pubmed:meshHeadingpubmed-meshheading:162676-M...lld:pubmed
pubmed-article:162676pubmed:year1975lld:pubmed
pubmed-article:162676pubmed:articleTitleA comparison of mazindol (Teronac) with diethylpropion in the treatment of exogenous obesity.lld:pubmed
pubmed-article:162676pubmed:affiliationMedical Department, Wander Pharmaceuticals Ltd, Feltham, Middlesex, England.lld:pubmed
pubmed-article:162676pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:162676pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:162676pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:162676pubmed:publicationTypeControlled Clinical Triallld:pubmed